GlassScriptPhysician profile
Lynn Patel
NPI 1952649642
$1,128.08
in general payments reported to CMS, 2019-2025
28 companies · $885 in 2025
The $885 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.85 · 2022: $91.98 · 2023: $124 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $101.04 | 2022-2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $88.33 | 2025 | |
| Sequel Med Tech, LLC | $81.80 | 2025 | Twiist |
| Antares Pharma, INC. | $71.38 | 2025 | Xyosted |
| Novo Nordisk INC | $56.52 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $56.27 | 2025 | Zepbound, Mounjaro, Jardiance |
| Tandem Diabetes Care, INC. | $53.60 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $50.74 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $46.77 | 2025 | Freestyle Libre 3 |
| Cochlear Americas | $45.93 | 2022-2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Xeris Pharmaceuticals, INC. | $40.86 | 2025 | Gvoke Hypopen |
| Stryker Corporation | $38.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.28 | 2025 | Jardiance |
| Recordati_rare_diseases_inc. | $33.46 | 2025 | Isturisa |
| Genzyme Corporation | $33.38 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.89 | 2025 | Evenity |
| Insulet Corporation | $30.00 | 2025 | Omnipod |
| Rhythm Pharmaceuticals, INC. | $29.57 | 2025 | Imcivree |
| Inspire Medical Systems, INC. | $26.08 | 2023 | Inspire |
| Madrigal Pharmaceuticals | $24.53 | 2025 | Rezdiffra |
| Optinose US, INC. | $22.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.93 | 2025 | Strensiq |
| Chiesi USA, INC. | $20.38 | 2025 | Mycapssa |
| Tolmar, INC. | $18.67 | 2025 | Jatenzo |
| Sanofi-Aventis U.S. LLC | $18.09 | 2025 | |
| Ascendis Pharma Endocrinology INC | $18.00 | 2025 | Yorvipath |
| Pulse Biosciences, INC. | $17.56 | 2025 | Cellfx |
| Currax Pharmaceuticals LLC | $15.85 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.